acid reflux and semaglutide Ozempic Heartburn: What's the Connection? GLP-1 Medications and GERD: Safety

Celebrities credit it for their transformations, social media influencers rave about it, and doctors recognize it as a research-backed breakthrough thats changing the conversation around weight loss

We can have a peak that's just as powerful in the afternoon as in the morning." Add protein balls, flatbreads, wraps, and baked goods into the food mix Lower carbs and sugars, increase protein and fiber #strategy #ceo | 20 comments on LinkedIn

Combining phentermine with tirzepatide raises serious safety questions

For this review, PubMed, SCOPUS, Embase, ProQuest, and Google Scholar databases were searched from inception through April 2020

The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities

Weight loss medications have rapidly moved from the margins of diabetes care into the center of conversations about wellness and the future of food